Cullinan Therapeutics, Inc. CGEM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s additional paid-in capital?
- Cullinan Therapeutics, Inc. (CGEM) reported additional paid-in capital of $1B in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Cullinan Therapeutics, Inc.'s additional paid-in capital increased by 3.7% year-over-year, from $968.07M to $1B.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s additional paid-in capital has grown at a 27.8% compound annual growth rate (CAGR), from $292.35M to $995.82M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.